- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 22, 2021Patent Trial and Appeal Board Finds Transitional Patent Eligible for PGR, Invalidates Claims, and Rejects Novel Argument That Bankruptcy Stay Ran out the PTAB Clock
-
November 19, 2021Robins Kaplan Secures $27.8 Million Jury Verdict on Behalf of Twin Cities Doctor
-
November 12, 2021Brendan Johnson Named a Litigation Trailblazer by The National Law Journal
-
December 6-8, 2021The 8th Annual IP Dealmakers Forum: Driving IP Transactions
-
December 9-10, 202122nd Annual Berkeley-Stanford Advanced Patent Law Institute
-
December 10, 2021LGBTQ Legal Services: Transgender Name Change Clinic
-
Winter 2021Avoiding Guilt by Association
-
Winter 2021Can You Keep a Secret? And Should You?
-
Winter 2021Quiet Trusts: The Benefits of Privacy in Estate Planning
-
December 3, 2021Markets Bounce Back and Look For Strong November Jobs Report
-
December 2, 2021EU Fines Big Banks Over Forex Spot Trading Cartels
-
December 1, 2021Fed to Hasten Taper in Bid to Target Persistent Inflation
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Fourth Quarter
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Otsuka Pharm. Co., Ltd. v. Optimus Pharma Pvt. Ltd., 20-1332 (D. Del.) | Oct. 1, 2020 | Hon. Leonard P. Stark | Rexulti® (brexipiprazole tablets) | RE48,059 |
| Vanda Pharms. Inc. v. Apotex Inc., 20-1333 (D. Del.) | Oct. 1, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) |
10,610,510 10,610,511 |
| Otsuka Pharm. Co., Ltd. v. MSN Pharms. Inc., 20-1334 (D. Del.) | Oct. 1, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) |
10,610,510 10,610,511 |
| Otsuka Pharm. Co., Ltd. v. Ajanta Pharma Ltd., 20-1335 (D. Del.) | Oct. 1, 2020 | Hon. Leonard P. Stark | Rexulti® (brexipiprazole tablets) | RE48,059 |
| UCB, Inc. v. Sunshine Lake Pharma Co., Ltd., 20-1343 (D. Del.) | Oct. 2, 2020 | Hon. Colm. F. Connolly | Briviact® (brivaracetam tablets) |
6,784,197 6,911,461 8,492,416 |
| Allergan USA, Inc. v. Hetero Labs Ltd., 20-1344 (D. Del.) | Oct. 2, 2020 | Hon. Richard G. Andrews | Viberzi® (eluxadoline tablets) | 7,741,356 |
| Actelion Pharms. Ltd. v. Laurus Labs Ltd., 20-13967 (D.N.J.) | Oct. 5, 2020 | Hon. Freda L. Wolfson | Opsumit® (macitentan tablets) | 7,094,781 |
| Almirall, LLC v. Torrent Pharms. Ltd., 20-1373 (D. Del.) | Oct. 9, 2020 | Hon. Maryellen Noreika | Aczone® Gel (dapsone) | 9,517,219 |
| Celgene Corp. v. Hetero Labs Ltd., 20-14389 (D.N.J.) | Oct. 13, 2020 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,977,357 8,193,219 |
| Pfizer Inc. v. Alembic Pharms., Inc., 20-1392 (D. Del.) | Oct. 16, 2020 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Cipla USA Inc., 20-1393 (D. Del.) | Oct. 16, 2020 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Mylan Pharms. Inc., 20-1395 (D. Del.) | Oct. 16, 2020 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-1396 (D. Del.) | Oct. 16, 2020 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-14580 (D.N.J.) | Oct. 16, 2020 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Mylan Pharms. Inc., 20-0244 (N.D.W.V.) | Oct. 16, 2020 | Hon. Thomas S. Kleeh | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Sun Pharm. Indus., Ltd, 20-1407 (D. Del.) | Oct. 20, 2020 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Sun Pharm. Indus., Ltd, 20-14717 (D.N.J.) | Oct. 20, 2020 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) | 10,723,730 |
| Dermira, Inc. v. Perrigo Pharma Int’l DAC, 20-1413 (D. Del.) | Oct. 21, 2020 | Hon. Colm F. Connolly | Qbrexza® (glycopyrronium cloth) |
8,618,160 9,744,105 10,052,267 8,859,610 9,259,414 10,004,717 10,543,192 10,548,875 |
| Teva Branded Pharm. Products R&D, Inc. v. Aurobindo Pharma Ltd., 20-14833 (D.N.J.) | Oct. 22, 2020 | Hon. Madeline Cox Arleo | Qvar® (beclomethasone dipropionate inhalation aerosol) |
9,463,289 9,808,587 10,022,509 10,022,510 10,086,156 10,561,808 10,695,512 |
| Galderma Labs., L.P. v. Zydus Pharms. (USA) Inc., 20-14857 (D.N.J.) | Oct. 22, 2020 | Hon. Freda L. Wolfson | Epiduo® Forte (adapalene / benzoyl peroxide gel) |
8,936,800 9,814,690 8,785,420 8,703,820 9,387,187 8,445,543 |
| Otsuka Pharm. Co., Ltd. v. Teva Pharms. USA, Inc., 20-1423 (D. Del.) | Oct. 23, 2020 | Hon. Leonard P. Stark | Rexulti® (brexipiprazole tablets) | RE48,059 |
| Novartis Pharms. Corp. v. Aurobindo Pharma Ltd., 20-1426 (D. Del.) | Oct. 23, 2020 | Hon. Leonard P. Stark | Xiidra® (lifitegrast ophthalmic solution) |
7,314,938 7,745,460 7,790,743 7,928,122 9,216,174 10,124,000 8,084,047 8,592,450 8,168,655 8,367,701 9,447,077 8,927,574 9,353,088 9,890,141 9,085,553 |
| Otsuka Pharm. Co., Ltd. v. MSN Labs. Pvt. Ltd., 20-1428 (D. Del.) | Oct. 23, 2020 | Hon. Leonard P. Stark | Rexulti® (brexipiprazole tablets) | RE48,059 |
| Teva Branded Pharm. Products R&D, Inc. v. Cipla Ltd., 20-14890 (D.N.J.) | Oct. 23, 2020 | Hon. Madeline Cox Arleo | Qvar® (beclomethasone dipropionate inhalation aerosol) | 10,695,512 |
| TherapeuticsMD, Inc. v. Amneal Pharms., Inc., 20-14933 (D.N.J.) | Oct. 23, 2020 | Hon. Freda L. Wolfson | Bijuva® (estradiol / progesterone capsules) | 10,806,740 |
| Allergan USA, Inc. v. Sun Pharm. Indus. Ltd., 20-1479 (D. Del.) | Oct. 29, 2020 | Hon. Richard G. Andrews | Viberzi® (eluxadoline tablets) | 7,741,356 |
| Fresenius Kabi USA, LLC v. Custopharm, Inc., 20-3254 (D. Col.) | Oct. 30, 2020 | Hon. Michael E. Hegarty | levothyroxine sodium for injection |
9,782,376 10,398,669 |
| Fresenius Kabi USA, LLC v. Custopharm, Inc., 20-15342 (D.N.J.) | Oct. 30, 2020 | Hon. Susan D. Wigenton | levothyroxine sodium for injection |
9,782,376 10,398,669 |
| Fresenius Kabi USA, LLC v. Custopharm, Inc., 20-1091 (D. Col.) | Oct. 30, 2020 | Hon. Lee Yeakel | levothyroxine sodium for injection |
9,782,376 10,398,669 |
| Merck Sharp & Dohme Corp. v. Ajanta Pharma Ltd., 20-1496 (D. Del.) | Nov. 4, 2020 | Hon. Richard G. Andrews | Janumet® (sitagliptin phosphate / metformin HCl tablets) | 7,326,708 |
| Otsuka Pharm. Co., Ltd. v. Prinston Pharm. Inc., 20-1502 (D. Del.) | Nov. 6, 2020 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | RE48,059 |
| Pfizer Inc. v. Aurobindo Pharma, Ltd., 20-1528 (D. Del.) | Nov. 13, 2020 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 10,723,730 |
| Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 20-1530 (D. Del.) | Nov. 13, 2020 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 10,723,730 |
| Otsuka Pharm. Co., Ltd. v. Hetero Labs Ltd., 20-1531 (D. Del.) | Nov. 13, 2020 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | RE48,059 |
| Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 20-16117 (D. Del.) | Nov. 13, 2020 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) | 10,723,730 |
| Sanofi-Aventis U.S. LLC v. Hong Kong King-Friend Industrial Co. Ltd., 20-1547 (D. Del.) | Nov. 17, 2020 | Hon. Richard G. Andrews | Jevtana® Kit (cabazitaxel for injection) |
10,583,110 10,716,777 |
| Otsuka Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 20-1581 (D. Del.) | Nov. 23, 2020 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | RE48,059 |
| Boehringer Ingelheim Pharms. Inc. v. Sun Pharm. Indus. Ltd., 20-1585 (D. Del.) | Nov. 23, 2020 | Hon. Colm F. Connolly | Trijardy XR® (empagliflozin / linagliptin / metformin extended-release tablets) | 7,579,449 |
| Astellas Pharma Inc. v. Sandoz Inc., 20-1589 (D. Del.) | Nov. 24, 2020 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 10,842,780 |
| Otsuka Pharm. Co., Ltd. v. Zenara Pharma Private Ltd., 20-1599 (D. Del.) | Nov. 24, 2020 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | RE48,059 |
| Adverio Pharma GmbH v. MSN Labs. Private Ltd., 20-1617 (D. Del.) | Nov. 25, 2020 | Hon. Leonard P. Stark | Adempas® (riociguat tablets) | 10,662,188 |
| Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., 20-1630 (D. Del.) | Nov. 30, 2020 | Hon. Richard G. Andrews | Vascepa® (icosapent ethyl capsules) |
9,700,537 8,642,077 10,568,861 |
| TherapeuticsMD, Inc. v. Teva Pharms. USA, Inc., 20-17496 (D.N.J.) | Nov. 30, 2020 | Hon. Brian R. Martinotti | Imvexxy® (estradiol vaginal insert) |
10,806,697 10,835,487 |
| Eli Lilly and Co. v. Shilpa Medicare Ltd., 20-3132 (S.D. Ind.) | Dec. 4, 2020 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed for injection) | 7,772,209 |
| Par Pharm., Inc. v. Eagle Pharms. Inc., 20-18319 (D.N.J.) | Dec. 7, 2020 | Hon. Brian R. Martinotti | Vasostrict® (vasopressin for injection) | 10,844,435 |
| Par Pharm., Inc. v. Amneal EU, Ltd., 20-18322 (D.N.J.) | Dec. 7, 2020 | Hon. Brian R. Martinotti | Vasostrict® (vasopressin for injection) | 10,844,435 |
| Par Pharm., Inc. v. Dr. Reddy’s Labs., Inc., 20-18328 (D.N.J.) | Dec. 7, 2020 | Hon. Brian R. Martinotti | Vasostrict® (vasopressin for injection) | 10,844,435 |
| Par Pharm., Inc. v. Aurobindo Pharma U.S.A., Inc., 20-18334 (D.N.J.) | Dec. 7, 2020 | Hon. Brian R. Martinotti | Vasostrict® (vasopressin for injection) | 10,844,435 |
| Merck Sharp & Dohme B.V. v. Teva Pharms. USA, Inc., 20-18972 (D.N.J.) | Dec. 14, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Acrotech Biopharma LLC v. Alembic Global Holding SA, 20-19295 (D.N.J.) | Dec. 15, 2020 | Hon. Freda L. Wolfson | Evomela® (captisol®-enabled melphalan HCl for injection) | 10,864,183 |
| Bausch Health Ireland Ltd. v. Lupin Ltd., 20-19379 (D.N.J.) | Dec. 16, 2020 | Hon. Renee Marie Bumb | Plenvu® (polyethylene glycol / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
10,780,112 10,792,306 |
| Galderma Labs., L.P. v. Zydus Pharms. (USA) Inc., 20-19578 (D.N.J.) | Dec. 17, 2020 | Hon. Renee Marie Bumb | Soolantra® (ivermectin cream) |
9,089,587 9,233,117 9,233,118 9,782,425 10,206,939 |
| Merz Pharms., LLC v. Aurobindo Pharma Ltd., 20-1760 (D. Del.) | Dec. 23, 2020 | Hon. Richard G. Andrews | Cuvposa® (glycopyrrolate oral solution) |
7,638,552 7,816,396 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. (USA) Inc., 20-1763 (D. Del.) | Dec. 23, 2020 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | RE48,059 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. (USA) Inc., 20-20269 (D.N.J.) | Dec. 23, 2020 | Hon. Michael A. Shipp | Rexulti® (brexpiprazole tablets) | RE48,059 |
| Eagle Pharms., Inc. v. Shilpa Medicare Ltd., 20-20270 (D.N.J.) | Dec. 23, 2020 | Hon. John Michael Vazquez | Pemfexy® (pemetrexed for injection) | 9,604,990 |
| Merz Pharms., LLC v. Aurobindo Pharma Ltd., 20-20346 (D.N.J.) | Dec. 28, 2020 | Hon. Freda L. Wolfson | Cuvposa® (glycopyrrolate oral solution) |
7,638,552 7,816,396 |
GENERICally Speaking Winter 2021
Related Professionals
GENERICally Speaking Winter 2021
VOL. 10, NO. 4 Related Publications
Third Quarter
ANDA Approvals
GENERICally Speaking Fall 2021
Third Quarter
ANDA Litigation Settlements
GENERICally Speaking Fall 2021
Third Quarter
Generic Launches
GENERICally Speaking Fall 2021
Third Quarter
New ANDA Cases
GENERICally Speaking Fall 2021
September 1, 2021
Belcher Pharms., LLC v. Hospira, Inc.
GENERICally Speaking Fall 2021
Related News
August 2, 2021
October 12, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.